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Introduction
Misoprostol, a prostaglandin E1, is effective in treating
non-steroidal anti-inflammatory drug-induced gastric
ulcers. It is orally administered, cheap, stable at room
temperature, and does not need to be stored in refrig-
erators. Misoprostol concentration in blood reaches
its peak 12 minutes after oral administration, with a
half-life of 21 minutes [1]. It has two effects on the
uterus. First, it is effective in cervical priming. Second,
it induces uterine muscles to contract, which causes the
cervix to dilate. The US Food and Drug Administration
(FDA) approved the auxiliary role of mifepristone
(RU486) in early pregnancy termination, and its exclu-
sive use in termination of full term pregnancy. After 
25 years of development, mifepristone is widely used to
induce abortion at different gestational stages, treating
postpartum hemorrhage, and priming the cervix before
surgery.
In addition to oral administration, misoprostol can
be administered via the vagina. As research has shown,
its absorption via the vagina is slow, taking 80 minutes
to reach a maximum level, but then its serum level
drops slowly; hence, its efficacy lasts relatively longer.
On the whole, serum misoprostol acid bioavailability
(concentration × time) is increased by three times when
vaginal administration is compared to oral adminis-
tration [2]. However, the results of vaginal absorption
vary greatly. Total absorption does not occur in some
patients despite hours of vaginal administration. Some
believe that absorption can be enhanced if a little water
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SUMMARY
Objective: Existing drug-induced abortion techniques involve oral administration of 200 mg of mifepristone,
followed by oral administration of 600 μg of misoprostol 48 hours later, but the effects are variable. As revealed
by recent research, sublingual and oral administrations of misoprostol are equally efficacious in terms of rapid
absorption, but the former lasts longer in serum. Hence, in the near future, sublingual administration of miso-
prostol may become the most effective way to induce abortion.
Materials and Methods: Women with intrauterine pregnancy up to 49 gestational days received vaginal ultra-
sonography, followed by oral administration of mifepristone 200 mg and sublingual administration of miso-
prostol 600 μg 48 hours later. They returned for follow-up consultations 3 and 14 days after. The definition of a
successfully induced complete medical abortion was that the abortion occurred without surgery or evacuating
the uterus.
Results: A total of 356 women underwent medical abortion; the complete abortion rate was 98.3% (350 women).
Medical abortion was unsuccessful in five (1.7%) women, who eventually had to undergo dilation and curettage.
Patients found the side effects to be bearable; the reported satisfaction rate was 89.9% (325 women).
Conclusion: Medical abortion for early termination of pregnancy should be achieved by oral administration of
mifepristone, followed by sublingual administration of misoprostol. [Taiwanese J Obstet Gynecol 2006;45(4):
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is applied to the vagina while vaginal administration is
underway. There is a need to find a method that enables
fast absorption and long-term efficacy.
Recent research shows that the mucous membrane
of the oral cavity has a very rich blood supply and is
therefore a potential drug delivery path. Misoprostol
sublingually administered for approximately 10–20 min-
utes can be fully absorbed without leaving any odor,
indicating that misoprostol sublingually administered
reaches a maximum level in serum in 26 minutes [1].
In another study, grass polygraphy of the uterus was used
to measure the uterine pressure of women whose early
pregnancy was to be terminated. About 11.5 minutes
after sublingual administration of misoprostol 400 μg,
the uterus began to contract, and uterine contraction
came to a climax in 52 minutes [3]. Comparison of oral
and vaginal administrations of the same dose show
that sublingual administration is as fast as oral admin-
istration in terms of efficacy, and sublingual admin-
istration also lasts as long as vaginal administration.
When sublingually administered, misoprostol can directly
act on the uterus and has high bioavailability. In con-
trast, its efficacy is not brought into full play when
orally administered and thereby metabolized by the
liver. Hence, in the near future, sublingual administra-
tion of misoprostol may become the most effective
way to induce abortion. We studied the effects of sub-
lingual administration of misoprostol on termination
of early pregnancy.
Materials and Methods
Between January 2002 and December 2005, a total of
356 women with early pregnancy requested medical
abortion. The program had the approval of the ethics
committee of Kuo General Hospital, Tainan, Taiwan.
Patients were eligible to receive medical abortion 
if they met the following criteria: (1) patient requests
medical abortion; (2) gestational age ≤ 49 days, as
confirmed by vaginal ultrasonography; (3) patient signs
an agreement of consent and is informed of the advan-
tages and risks of medical abortion and the necessity
of receiving surgical abortion in case of medical abortion
failure; and (4) patient promises to attend follow-up
appointments.
No medical abortion was performed on pregnant
women who met any of the following exclusion criteria:
(1) drug allergy to prostaglandins; (2) symptoms of
threatened abortion; (3) medical history of diseases
related to the heart, respiratory system, kidneys, liver, or
adrenal gland; (4) medical history of thromboembol-
ism, hypertension, coagulopathy, or diabetes mellitus;
(5) medical history of ultrasonographic or uterine pathol-
ogy; and (6) active pelvic infection.
Four clinic visits were scheduled. At visit 1 (day 1),
patients received oral mifepristone 200 mg, and stayed
in the hospital for 1 hour of observation before being
discharged. Patients were told that they should visit
the hospital again promptly if they experienced marked
symptoms or excessive hemorrhage.
At visit 2 (day 3), 48 hours after oral administra-
tion of mifepristone, patients visited the hospital again
to receive sublingual administration of misoprostol
600 μg by taking three 200 μg capsules. The misopros-
tol capsules were put under the tongue, and all the
capsules were completely dissolved and absorbed
10–15 minutes later. After that, they stayed in the hos-
pital for 1 hour of observation before being discharged
with three tablets of acetaminophen 500 mg, to be
taken every 6 hours should they have lower abdominal
pain.
At visit 3 (day 6), patients visited the hospital again
for vaginal ultrasound. Patients were instructed to be
alert for the expulsion of the conceptus and to note the
amount of bleeding, as well as to record all symptoms
such as abdominal pain, shivering, vomiting, nausea,
headache, and diarrhea. If the patient had menses as
usual or complained of menorrhagia, and the gesta-
tional sac was no longer visible on ultrasound, then
the patient was scheduled to visit the hospital 8 days
later. If the gestational sac was intact on ultrasound,
surgical abortion was recommended, and the patient
received gynecologic examination.
At visit 4 (day 14), the physician asked the patient
whether she had had bleeding, and performed trans-
vaginal ultrasonography. Normal ultrasonographic find-
ings indicated the end of therapy, although a follow-up
appointment 1 week later was made when necessary.
The definition of a successfully induced complete med-
ical abortion was that the abortion occurred without
surgery or evacuating the uterus.
At the end of therapy, patients completed a ques-
tionnaire to evaluate whether the medical abortion had
been performed to their satisfaction. The questionnaire
consisted of multiple choice questions with the follow-
ing choices: strongly disagree; disagree; neutral; agree;
strongly agree.
Results
During the study period, medical abortion was per-
formed in 356 women. Their mean age was 24.8 years
(range, 18–40 years), and mean gestational age was
45.2 days (range, 36–49 days). Of the 356 women,
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206 (57.9%) were nulliparous, 56 (15.7%) were primi-
parous, and 94 (26.4%) were multiparous.
The vast majority of patients (350, 98.3%) had com-
plete medical abortion. However, medical abortion was
unsuccessful in five (1.7%) women (3 cases of incom-
plete abortion, 2 of gestational sac remaining), who
eventually had to undergo dilation and curettage to
evacuate the uterus. The mean induction to abortion
interval was 3.5 hours (range, 1.5–6 hours). The mean
bleeding duration was 12.5 days (range, 7–36 days).
Reported side effects were abdominal pain (84.8%),
nausea (21.9%), fever (16.8%), shivering (14.9%), diar-
rhea (7.8%), headache (5.3%), and vomiting (3.9%),
although all were mild and did not require any medi-
cation except analgesics. No patient had infection,
severe hemorrhage or any need for blood transfusion.
The rates for how much patients agreed that the pro-
cedure had been performed to their satisfaction were:
strongly agree 64.9%; agree 25%; neutral 5.8%; dis-
agree 4.3%; resulting in a satisfaction rate of 89.9%
(325 patients).
Discussion
This study shows that sublingual administration of
misoprostol is an effective and safe treatment option
for the termination of a short pregnancy < 7 gesta-
tional weeks. The most widely used method of early
abortion involves oral administration of mifepristone
600 mg followed by oral administration of misopros-
tol 400 μg 48 hours later, which results in a complete
abortion rate of 87–96.9% [4–7], a somewhat variable
therapeutic result. However, mifepristone pharmaco-
kinetic studies show equivalent serum levels for doses
≥ 100 mg [8]. A dose of 200 mg has been shown to
have similar effectiveness for medical abortion as a
600 mg dose [9]. Thus, we selected a dose of 200 mg
misoprostol for this study. Some research shows that
the therapeutic effect is even better when oral adminis-
tration of mifepristone is followed by vaginal adminis-
tration of misoprostol; however, some young women
are reluctant to receive vaginal administration for pri-
vacy reasons.
In their 2001 pilot study, Tang and Ho gave 25
patients (mean gestational age, 10.6 weeks) sublingual
misoprostol 600 μg only, and the sublingual adminis-
tration of misoprostol could be repeated every 3 hours
for a maximum of three times [10]. Twenty-three (92%)
patients had complete abortion, with side effects like
diarrhea (60%) and fever (38°C; 60%). In conclusion,
the sole sublingual administration of misoprostol is a
very effective way to induce late abortion.
In addition, Tang et al compared the pharmaco-
kinetics of different routes of misoprostol administra-
tion, namely sublingual, oral, per vagina, and vaginal
with the addition of water, by measuring misoprostol
acid in venous blood samples using gas chromatogra-
phy/tandem mass spectrometry [1]. Sublingual miso-
prostol achieved the highest peak serum concentration
of misoprostol acid, and the area under the curve with
sublingual misoprostol was also significantly higher
than those in the other groups, suggesting that it may
be the most potent way of administration.
In 2003, Cheung et al reported giving sublingual
misoprostol 400 μg every 3 hours, for three times, 
to 50 women with pregnancies < 7 weeks’ gestation.
Complete abortion was achieved in 86% of women;
4% had incomplete abortion and 10% proceeded with
their pregnancy [11]. The abortion took a mean of 14
hours to finish, and bleeding took 20 days on average
to stop; there were few side effects. Sole sublingual
administration of misoprostol is a very effective way to
induce abortion in women with pregnancies < 7 gesta-
tional weeks. Although the therapeutic effect would be
even better if mifepristone is used or the dosage of
misoprostol is increased, the sole sublingual adminis-
tration of misoprostol is an effective way to induce
abortion in countries where mifepristone is prohibited.
In 2003, Tang et al reported giving oral mifepris-
tone 200 mg followed by sublingual misoprostol 800μg
48 hours later to 29 women (< 7 gestational weeks)
[12]. All patients (100%) had complete abortion. The
side effects mainly involved the stomach and intestines,
and included fever and shivering, but were mostly tol-
erable and did not require treatment. Similarly, also in
2003, Hamoda et al gave oral mifepristone 200 mg
followed by sublingual misoprostol 600 μg 36–48 hours
later to 96 women with pregnancies < 63 days’ gesta-
tion; 98.9% of patients had complete abortion, with
very mild side effects [13].
In conclusion, to terminate early pregnancy by med-
ical abortion, sublingual administration of misoprostol
following oral administration of mifepristone as well
as sole sublingual administration of misoprostol are
effective therapeutic methods. In this study, oral admin-
istration of mifepristone 200 mg followed by sublin-
gual administration of misoprostol 600 μg 48 hours
later resulted in a complete abortion rate of 98.5% of
pregnancies ≤ 49 days’ gestation, with tolerable side
effects and a high satisfaction rate of 89.9%. However,
further study is required to determine the optimal
dosage and times of sublingual misoprostol adminis-
tration. Since sublingual administration of misoprostol
bypasses metabolism by the gastroenterologic system,
its efficacy is theoretically better than that of oral
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misoprostol. Hence, in the near future, we will conduct
a comparative study on the therapeutic effects of sub-
lingual versus oral administration of misoprostol of the
same dosage, following oral mifepristone, on abortion.
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